Market revenue in 2023 | USD 309.7 million |
Market revenue in 2030 | USD 590.5 million |
Growth rate | 9.7% (CAGR from 2023 to 2030) |
Largest segment | Instruments |
Fastest growing segment | Software |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Reagents & Consumables, Software, Accessories, Services |
Key market players worldwide | Danaher Corp, BD, Sysmex Corp, Agilent Technologies, Apogee Enterprises Inc, Bio-Rad Laboratories Inc Class A, Thermo Fisher Scientific Inc, Wipro Ltd ADR, Diasorin SpA, Miltenyi Biotec, Sony Group Corp |
Instruments was the largest segment with a revenue share of 37.13% in 2023. Horizon Databook has segmented the China flow cytometry market based on instruments, reagents & consumables, software, accessories, services covering the revenue growth of each sub-segment from 2018 to 2030.
The flow cytometry market in China is expected to grow at a lucrative rate during the forecast period. This fast growth can be attributed to the robust growth of pharmaceutical, biotechnology, and biopharmaceutical sectors in China.
In 2019, the Beijing Xisike Clinical Oncology Research Foundation granted funds to support the expansion of clinical and scientific research in China. In addition, extensive research activities have been conducted by several Chinese pharmaceutical companies for the development of novel vaccines or therapies for COVID-19.
Increased R&D initiatives are anticipated to significantly boost the demand for flow cytometry products in the country, thus supporting market growth. Moreover, key players are undertaking both organic and inorganic growth strategies to gain a competitive edge in China flow cytometry market.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account